Related references
Note: Only part of the references are listed.Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study
Robert F. Storey et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Tailored Clopidogrel Loading Dose According to Platelet Reactivity Monitoring to Prevent Acute and Subacute Stent Thrombosis
Laurent Bonello et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
2009 Focused Updates: ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction (Updating the 2004 Guideline and 2007 Focused Update) and ACC/AHA/SCAI Guidelines on Percutaneous Coronary Intervention (Updating the 2005 Guideline and 2007 Focused Update) A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines
Frederick G. Kushner et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2009)
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
Lars Wallentin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Platelet Inhibition with Cangrelor in Patients Undergoing PCI.
Robert A. Harrington et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Aspirin Resistance
Udaya S. Tantry et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2009)
Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study
Laurent Bonello et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Stephen D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment
Flavio Airoldi et al.
CIRCULATION (2007)
Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events
L. Bonello et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats
William A. Schumacher et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2007)
Clinical end points in coronary stent trials - A case for standardized definitions
Donald E. Cutlip et al.
CIRCULATION (2007)
Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives
Dominick J. Angiolillo et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting
Thomas Cuisset et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes - The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial
Gilles Montalescot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
High post-treatment platelet reactivity identified low-responders to dual antiplatelet therapy at increased risk of recurrent cardiovascular events after stenting for acute coronary syndrome
T Cuisset et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2006)
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
W Hochholzer et al.
CIRCULATION (2005)
The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting
PA Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention - Results from the ARMYDA-2 (Antiplatelet therapy for reduction of MYocardial Damage during Angioplasty) study
G Patti et al.
CIRCULATION (2005)
Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases
B Aleil et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2005)
Limited early antiplatelet effect of 300 mg clopidogrel in patients with aspirin therapy undergoing percutaneous coronary interventions
A Lepäntalo et al.
EUROPEAN HEART JOURNAL (2004)
Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction
S Matetzky et al.
CIRCULATION (2004)
High clopidogrel loading dose during coronary stenting:: effects on drug response and interindividual variability
DJ Angiolillo et al.
EUROPEAN HEART JOURNAL (2004)
Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation
P Barragan et al.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS (2003)
Clopidogrel for coronary stenting - Response variability, drug resistance, and the effect of pretreatment platelet reactivity
PA Gurbel et al.
CIRCULATION (2003)
Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
SR Mehta et al.
LANCET (2001)
Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting - The Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS)
ME Bertrand et al.
CIRCULATION (2000)
Share Paper
